Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial | Zendy

Aditya Bardia | Zendy; Marina Parton | Zendy; Sherko Kümmel | Zendy; Laura GarcíaEstévez | Zendy; ChiunSheng Huang | Zendy; Javier Cortés | Zendy; Manuel RuízBorrego | Zendy; Melinda L. Telli | Zendy; Paloma Martín-Martorell | Zendy; Rafael LópezLópez | Zendy; J. Thaddeus Beck | Zendy; Roohi IsmailKhan | Zendy; ShinCheh Chen | Zendy; Sara A. Hurvitz | Zendy; Ingrid A. Mayer | Zendy; D. Carreon | Zendy; Scott B. Cameron | Zendy; Serena G. Liao | Zendy; José Baselga | Zendy; SungBae Kim | Zendy

Open Access

Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial

Author(s) -

Aditya Bardia,

Marina Parton,

Sherko Kümmel,

Laura GarcíaEstévez,

ChiunSheng Huang,

Javier Cortés,

Manuel RuízBorrego,

Melinda L. Telli,

Paloma Martín-Martorell,

Rafael LópezLópez,

J. Thaddeus Beck,

Roohi IsmailKhan,

ShinCheh Chen,

Sara A. Hurvitz,

Ingrid A. Mayer,

D. Carreon,

Scott B. Cameron,

Serena G. Liao,

José Baselga,

SungBae Kim

Publication year - 2018

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2017.74.8392

Subject(s) - medicine , breast cancer , oncology , neutropenia , gastroenterology , cancer , gene signature , chemotherapy , chemistry , gene , biochemistry , gene expression

This neoadjuvant trial provides evidence supporting a biomarker-driven targeted therapy approach for selected patients with GS-positive TNBC and demonstrates the utility of a neoadjuvant trial for biomarker validation and drug development, but also highlights toxicity risk. Future neoadjuvant clinical trials should carefully weigh these considerations for targeted therapy development in biomarker-defined TNBC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research